Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain

NCT03204331 is registered in ClinicalTrials.gov with Myovant Sciences GmbH as lead sponsor.

NCT NCT03204331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03204331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Lead sponsor
Myovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2017
Completion date
May 31, 2021
Enrollment
623 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis related pain